Last updated on February 2018

Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: HEPATOCELLULAR CARCINOMA | Relapse
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Age 18-75 years
  2. Hepatocellular carcinoma confirmed by pathology
  3. No macroscopic tumor thrombus vascular invasion and distant metastasis
  4. R0 resectionclean resection margin both macroscopically and microscopically
  5. MVI confirmed by pathology
  6. ECOG 0-1
  7. Child-Pugh stage A
  8. WBC > 310E9/LHB > 90 G/LPLT > 5010E9/L
  9. ALTAST not exceeding 5 times of the upper limit of normal valueCRETBIL not exceeding 1.5 times of the upper limit of normal value

Exclusion Criteria:

  1. Tumor rupture or invading to adjacent organs
  2. Patients who underwent liver transplantation
  3. Past history of or simultaneously receiving other anti-cancer therapy (such as TACE, chemotherapy, radiotherapy and othersand immune cell infusion therapy
  4. Uncontrolled cardiovascular and cerebrovascular diseases
  5. History of gastrointestinal bleeding within 6 months
  6. Active infection other than HBV, HCV
  7. Postoperative complications, not suitable to take Sorafenib (such as long term use of drainage due to bile leakage, poor wound healing and others)
  8. Confirmed liver cancer recurrence or metastasis within 4 weeks after hepatectomy
  9. Poor compliance, cannot adhere to regular follow up
  10. Diagnosed with other original malignant tumors other than HCC

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.